Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Factors Influencing Drug Absorption: Pharmaceutical Parameters01:28

Factors Influencing Drug Absorption: Pharmaceutical Parameters

377
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
377
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

134
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
134
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

280
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
280
Factors Affecting Dissolution: Particle Size and Effective Surface Area01:23

Factors Affecting Dissolution: Particle Size and Effective Surface Area

1.5K
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
1.5K
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry01:20

Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry

480
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
480
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism01:21

Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism

645
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
645

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Effect of Amorphization on the Punch Sticking Propensity of Organic Powders.

Molecular pharmaceutics·2026
Same author

A Comparative Study of the Tabletability of Amorphous and Crystalline Forms of Organic Drugs.

Molecular pharmaceutics·2025
Same author

Unveiling the Structure of Anhydrous Sodium Valproate with 3D Electron Diffraction and a Facile Sample Preparation Workflow.

ACS central science·2025
Same author

A Global Analysis of the Mechanical Properties of Organic Glasses Below <i>T</i><sub>g</sub>.

Molecular pharmaceutics·2025
Same author

How elastically flexible can molecular crystals be? - a new record.

Chemical science·2025
Same author

Decreased Crystal Plasticity by Solvation - the Case of Levofloxacin Acesulfame.

Molecular pharmaceutics·2025

相关实验视频

Updated: Jan 8, 2026

Formation of Dispersible Taohong Siwu Tablets
05:44

Formation of Dispersible Taohong Siwu Tablets

Published on: February 3, 2023

2.0K

在干颗粒系统中,可平板化翻转.

Zijian Wang1, Chenguang Wang1, Tianxiang Gao1

  • 1Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, MN, 55455, USA.

Pharmaceutical research
|December 17, 2025
PubMed
概括
此摘要是机器生成的。

在干颗粒配方中研究了可片性翻转现象 (TFP). 颗粒的多孔性和酸水平通过影响粘合面积和强度,影响平板质量,对TFP产生了重大影响.

关键词:
结合区域的结合区域是结合强度是因为结合强度.颗粒化 颗粒化 颗粒化塑性是一种可塑性.在平板可用性翻转.

更多相关视频

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

1.4K
A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients
11:27

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients

Published on: August 9, 2022

2.4K

相关实验视频

Last Updated: Jan 8, 2026

Formation of Dispersible Taohong Siwu Tablets
05:44

Formation of Dispersible Taohong Siwu Tablets

Published on: February 3, 2023

2.0K
Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

1.4K
A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients
11:27

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients

Published on: August 9, 2022

2.4K

科学领域:

  • 制药科学 制药科学
  • 材料科学 材料科学 材料科学
  • 化学工程是化学工程的重要组成部分.

背景情况:

  • 在直接压缩中观察到平板性翻转现象 (TFP),其中较少可变形的活性药物成分 (API) 与辅助剂的平板性得到改善.
  • 颗粒剂,特别是干颗粒剂对TFP的影响在很大程度上仍未被描述,需要进一步调查.

研究的目的:

  • 探索干颗粒配方中TFP的发生和潜在机制.
  • 评估颗粒多孔性和酸 (MgSt) 含量对TFP的影响.

主要方法:

  • 乙氨基 (APAP) 和布洛芬 (IBU) 被用作干颗粒的模型API.
  • 通过调整压缩压力,在两个孔隙级别 (9%和19%) 准备颗粒.
  • 用不同的微粒外MgSt度评估了可平板性,粘合面积 (BA) 和粘合强度 (BS).

主要成果:

  • 较高孔径颗粒 (19%) 通过碎片化呈现TFP,类似于非颗粒混合物.
  • 较低孔径颗粒 (9%) 显示TFP受BA和BS相互作用的控制,尽管BA较低,但APAP由于BS较高而保持TFP.
  • 结合≥1%的MgSt减少了BS差异,通过支持更软的IBU颗粒的更高可平板性来消除TFP.

结论:

  • 粘合面积-粘合强度 (BA-BS) 框架有效地解释了颗粒系统中的TFP.
  • 控制颗粒孔隙性和MgSt水平对于优化干颗粒处理中的可平板性至关重要.
  • 了解这些因素对于预测和管理制药制造中的TFP至关重要.